Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults
Search results
1070 results
-
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not
-
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non
-
Eculizumab for treating refractory myasthenia gravis (terminated appraisal) (TA636)
NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis because Alexion Pharma UK did not provide an evidence
-
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
NICE is unable to make a recommendation about the use in the NHS of ranibizumab (Lucentis) for treating diabetic retinopathy because Novartis did not provide an
-
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults
-
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults
-
Guidance on the use of liquid-based cytology for cervical screening (TA69)
Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening
-
Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)
Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)
-
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or
-
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults
-
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)
Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for
-
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell
-
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults
-
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1
-
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) (TA646)
NICE is unable to make a recommendation on glasdegib with chemotherapy for untreated acute myeloid leukaemia because Pfizer did not provide an evidence
-
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)
NICE is unable to make a recommendation about the use in the NHS of eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK
-
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
-
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency
-
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer
-
Capecitabine for the treatment of advanced gastric cancer (TA191)
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults
-
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)
-
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)
-
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor
-
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer
-
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
-
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C
-
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease
-
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
-
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)
Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)
-
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
-
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults
-
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)
-
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)
Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events
-
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women
-
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer
-
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)
Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years
-
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for treating non-small-cell lung cancer (NSCLC)
-
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion
-
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
-
Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)
NICE is unable to make a recommendation about the use in the NHS of agomelatine for major depressive episodes because no evidence submission was received
-
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women
-
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) (TA206)
NICE is unable to make a recommendation about the use in the NHS of bendamustine for treating indolent (low grade) non-Hodgkin's lymphoma that is refractory
-
Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (TA207)
NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence
-
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)
-
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
-
Golimumab for the treatment of psoriatic arthritis (TA220)
Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis
-
Mifamurtide for the treatment of osteosarcoma (TA235)
Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)